Transaction DateRecipientSharesTypePriceValue
11th April 2019Roger Hawley454,545Open or private purchase$1.10$499,999.50
29th March 2019Roger Hawley15,700Open or private sale$55.00$863,500.00
29th March 2019Roger Hawley5,000Open or private sale$55.00$275,000.00
29th March 2019Roger Hawley5,000Exercise of derivative$20.00$100,000.00
29th March 2019Roger Hawley15,700Exercise of derivative$33.92$532,544.00
14th March 2019Roger Hawley38,789Open or private sale$52.93$2,053,260.80
13th March 2019Roger Hawley21,211Open or private sale$53.10$1,126,215.01
1st March 2019Roger Hawley3,125Exercise of derivative$32.00$100,000.00
1st March 2019Roger Hawley1,175Exercise of derivative$33.92$39,856.00
1st March 2019Roger Hawley4,300Open or private sale$50.00$215,000.00
Cerulean Pharma
Cerulean Pharma logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Ticker: CERU
Sector: Unknown
Industry: Unknown
SEC Central Index Key (CIK): 1401914
Exchange: None
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $5 M (11%)
Assets, Current: $8 M (20%)
Property, Plant and Equipment, Net: $55 Th (-13%)
Other Assets, Noncurrent: $739 Th (-21%)
Assets: $9 M (15%)
Accounts Payable, Current: $2 M (58%)
Accrued Liabilities, Current: $2 M (-21%)
Liabilities, Current: $6 M (8%)
Liabilities: $8 M (17%)
Common Stock, Value, Issued: $3 Th (44%)
Common Stock, Shares, Issued: $29 M (44%)
Additional Paid in Capital, Common Stock: $56 M (25%)
Retained Earnings (Accumulated Deficit): $55 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $113 Th (10%)
Stockholders' Equity (Parent): $311 Th (0%)
Liabilities and Equity: $9 M (15%)
Research and Development: $6 M (-30%)
General and Administrative Expenses: $2 M (-54%)
Operating Income/Loss: $7 M (-37%)